Bionano genomics, inc (BNGO)
CashFlow / Yearly
Dec'19Dec'18Dec'17
Operating activities:
Net loss

-29,815

-18,496

-23,365

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense

1,127

1,320

1,504

Change in fair value of preferred stock warrants and expirations

0

-3,991

-751

Non-cash interest

883

750

0

Stock-based compensation

1,346

1,193

382

Provision for bad debt expense

554

-262

262

Inventory Write-down

0

1,287

364

Impairment of property and equipment

-

-

604

Accretion of debt discount

-

-

-96

Loss on debt extinguishment

-1,333

-342

0

(Gain) loss on disposal of fixed assets

-11

0

-

Fair value of warrants issued for services

0

165

0

Other items

0

-115

-

Changes in operating assets and liabilities:
Accounts receivable

2,374

900

1,767

Inventory

3,641

418

336

Prepaid expenses and other current assets

245

-152

-770

Accounts payable

1,362

-954

1,541

Accrued expenses and contract liabilities

-73

-247

-123

Net Cash Provided by (Used in) Operating Activities

-29,500

-19,943

-20,817

Investing activities:
Purchases of property and equipment

61

331

1,017

Net cash used in investing activities

-61

-331

-1,017

Financing activities:
Proceeds from issuance of debt, net of issuance costs

19,134

23,830

-

Proceeds from issuance of long-term debt, net of issuance costs

-

-

0

Proceeds from borrowing from line of credit

5,113

0

0

Repayments of Lines of Credit

3,615

0

-

Repayment of long-term debt

10,812

7,447

0

Proceeds from issuance of common stock, net of issuance costs

-

-

17,593

Proceeds from sale of common stock, net of offering costs

19,556

19,389

0

Proceeds from sale of common stock under employee stock purchase plan

141

-

0

Proceeds from warrant and option exercises

860

3

-

Proceeds from option exercises

-

-

14

Net cash provided by financing activities

30,379

35,776

17,607

Net increase in cash and cash equivalents

788

15,500

-4,227

Supplemental disclosure of non-cash financing and investing activity:
Fair value of warrants issued with debt classified as a liability

-

-

0

Transfer of instruments and servers from inventory into property and equipment

1,266

0

75

Transfer of instruments and servers from property and equipment into inventory

0

242

-

Debt Conversion, Converted Instrument, Amount

0

14,898

0

Fair value of stock and warrants issued in conjunction with debt

831

176

-

Issue stock for covenant waiver

504

0

-

Reduce warrant exercise price for covenant waiver

45

0

-

Non-cash portion of debt extinguishment

521

0

-

Final payment fee due in connection with the repayment of debt classified within other long-term liabilities

0

400

0

Conversion of preferred stock warrants into common stock and common stock warrants

0

84

0

Property and equipment costs incurred but not paid included in accounts payable and accrued expenses

0

3

11

Issuance of Stock and Warrants for Services or Claims

0

165

0

Supplementary disclosure of cash flow information
Interest paid

1,277

700

534